Literature DB >> 18972907

Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature.

Olarn Arpornchayanon1, Taninnit Leerapun.   

Abstract

Giant cell tumor is a benign locally aggressive tumor. The standard treatment is en bloc resection followed by major reconstructive surgery, or extended curettage conjunction with bone grafting or the use of bone cement implantations. Surgical treatment of giant cell tumor at the sacrum is associated with high morbidity, and local recurrence. The authors present a case of giant cell tumor at the sacrum treated with intravenous 4 mg zoledronate every 4 weeks for seven courses followed with curettage and cement implantation. At two years follow-up, the patient had no pain, no neurological deficit, and no local recurrence. The patient's gait was normal. From the present study, the authors demonstrate the effectiveness of zoledronate for treatment of giant cell tumor at the sacrum. It can reduce the morbidity from major surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972907

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  9 in total

1.  Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage.

Authors:  Kun-Hui Chen; Po-Kuei Wu; Cheng-Fong Chen; Wei-Ming Chen
Journal:  Eur Spine J       Date:  2015-05-05       Impact factor: 3.134

2.  Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent.

Authors:  Roberta Cosso; Vincenzo Nuzzo; Alfonso Zuccoli; Maria Luisa Brandi; Alberto Falchetti
Journal:  Clin Cases Miner Bone Metab       Date:  2010-05

3.  Alternative approach to treatment of unusual site giant cell tumor at cervical spine: A case report and review of literature.

Authors:  Seyed Reza Mousavi; Alireza Rezvani; Keyvan Eghbal; Mohammadhadi Amir Shahpari Motlagh; Amir Reza Dehghanian; Sanaz Taherpour; Majidreza Farrokhi
Journal:  J Craniovertebr Junction Spine       Date:  2022-06-13

4.  Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.

Authors:  Maurice Balke; Laura Campanacci; Carsten Gebert; Piero Picci; Max Gibbons; Richard Taylor; Pancras Hogendoorn; Judith Kroep; John Wass; Nicholas Athanasou
Journal:  BMC Cancer       Date:  2010-08-29       Impact factor: 4.430

5.  L4 and L5 spondylectomy for en bloc resection of giant cell tumor and review of the literature.

Authors:  David R Santiago-Dieppa; Lee S Hwang; Ali Bydon; Ziya L Gokaslan; Edward F McCarthy; Timothy F Witham
Journal:  Evid Based Spine Care J       Date:  2014-10

6.  Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.

Authors:  Astrid Lipplaa; Judith R Kroep; Lizz van der Heijden; Paul C Jutte; Pancras C W Hogendoorn; Sander Dijkstra; Hans Gelderblom
Journal:  Oncologist       Date:  2019-04-30

7.  Comparison of Local and Intravenous Zoledronic Acid on Histopathology and Recurrence Rate after Extended Curettage in Giant Cell Tumors of Proximal Tibia: A Prospective Study.

Authors:  Sakib Arfee; Anzar Tariq Malik; Ashish Nehru; Umar Ali; Akib Arfee; Adnan Aadil Arfee
Journal:  J Pharm Bioallied Sci       Date:  2022-07-13

8.  Effect of Intravenous Zoledronic Acid on Histopathology and Recurrence after Extended Curettage in Giant Cell Tumors of Bone: A Comparative Prospective Study.

Authors:  Zile Singh Kundu; Rajeev Sen; Ankur Dhiman; Pankaj Sharma; Ramchander Siwach; Parveen Rana
Journal:  Indian J Orthop       Date:  2018 Jan-Feb       Impact factor: 1.251

9.  Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone.

Authors:  Yi Luo; Fan Tang; Yitian Wang; Yong Zhou; Li Min; Wenli Zhang; Rui Shi; Hong Duan; Chongqi Tu
Journal:  Cancer Manag Res       Date:  2018-07-05       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.